RT info:eu-repo/semantics/article
T1 Cardiotoxicity secondary to immune checkpoint inhibitors in the elderly: Safety in real-world data
A1 Toribio García, Irene
A1 Olivares Hernández, Alejandro
A1 Miramontes González, José Pablo
A1 Posado Domínguez, Luis
A1 Martín García, Ana
A1 Eiros Bachiller, Rocío
A1 Figuero Pérez, Luis
A1 Garijo Martínez, María
A1 Roldán Ruiz, Jonnathan
A1 Bellido Hernández, Lorena
A1 Fonseca Sánchez, Emilio
A1 Sánchez, Pedro Luis
A1 Barco Morillo, Edel del
K1 Immunotherapy
K1 Inmunoterapia
K1 Cancer - Immunotherapy
K1 Cáncer - Inmunoterapia
K1 Oncology
K1 immune checkpoint inhibitors
K1 Cancer - Immunological aspects
K1 Older people
K1 Personas de edad
K1 Cardiotoxicity
K1 Cardiovascular system - Diseases
K1 Cardiovascular, Aparato - Enfermedades
K1 3201.01 Oncología
K1 3207.04 Patología Cardiovascular
AB Simple Summary: Immunotherapy is the mainstay treatment for most solid tumours. However, its cardiotoxicity is not yet known and studied, and its uncertainty is even greater in elderly patients. For this reason, this ambispective study was conducted in 195 patients over 70 years of age who were treated with immunotherapy. The percentage of patients with cardiotoxicity was 1.54%; 1.35% of patients with previous heart disease were diagnosed with cardiotoxicity, and 1.65% of those without previous heart disease were diagnosed with cardiotoxicity. The median time from the initiation of treatment until the cardiac event was 45 days. The most frequent toxicity was myocarditis, which was identified in 66.7% of patients, followed by arrhythmias in 33.3% of patients. In conclusion, immunotherapy is shown to be a safe treatment in elderly cancer patients in terms of cardiotoxicity.
PB MDPI
SN 2072-6694
YR 2023
FD 2023
LK https://uvadoc.uva.es/handle/10324/66668
UL https://uvadoc.uva.es/handle/10324/66668
LA eng
NO Cancers, 2023, Vol. 15, Nº. 17, 4293
NO Producción Científica
DS UVaDOC
RD 08-ene-2025